ald

ELOVL1-IN-1 (1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide) 是ELOVL1抑制剂，能够降低超长链脂肪酸的水平，可用于肾上腺脑白质营养不良的研究。

Ald-C2-PEG4-azide is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-CH2-PEG3-azide is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Ald-CH2-PEG4-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-CH2-PEG3-CH2-Boc, a PEG- and Alkyl/ether-based PROTAC linker, is utilized for the synthesis of SGK3 kinase PROTAC degrader[1].

Ald-CH2-PEG5-azide is a non-cleavable linker consisting of a five unit PEG chain, commonly employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Ald-CH2-PEG5-Boc is a PEG- and Alkyl/ether-based PROTAC linker suitable for synthesizing PROTACs[1].

Ald-PEG1-C2-Boc is an alkyl-ether-based linker utilized for the synthesis of PROTACs, a class of small molecules that induce targeted protein degradation[1].

Ald-Ph-amido-C2-PEG2-amine is a polyethylene glycol (PEG)-based linker utilized for the synthesis of PROteolysis TArgeting Chimeras (PROTACs)[1].

Ald-Ph-amido-C2-PEG3-NH-Boc is a polyethylene glycol (PEG)-based bifunctional linker utilized for the synthesis of Proteolysis Targeting Chimeras (PROTACs)[1].

Ald-Ph-amido-PEG2-C2-Boc is a polyethylene glycol (PEG)-based linker utilized for the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Ald-Ph-amido-PEG4-C2-NHS ester is a non-cleavable 4-unit PEG linker employed in antibody-drug conjugation (ADC) to connect antibodies with drugs.

Ald-Ph-PEG2-NH-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-Ph-PEG4-NH-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-Ph-PEG6-acid is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-Ph-PEG6-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-Ph-amido-PEG2-C2-acid is a PEG-based PROTAC linker utilized for synthesizing PROTACs[1].

Ald-Ph-amido-PEG2-C2-NHS ester is a non-cleavable 2-unit PEG linker employed in antibody-drug conjugation (ADC) to connect antibodies with drugs.

Ald-Ph-amido-PEG3-C2-NH2 is a PEG-based PROTAC linker employed in PROTACs synthesis[1].

Ald-Ph-amido-PEG4-C2-acid is a noncleavable linker utilized in the development of antibody-drug conjugates (ADC).

Ald-CH2-PEG10-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-CH2-PEG8-azide is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-Ph-amido-C2-PEG3-azide is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Ald-Ph-amido-PEG23-OPSS is a cleavable 23-unit polyethylene glycol linker commonly employed for the synthesis of antibody-drug conjugates (ADCs)[1].